Literature DB >> 15553208

Non small cell lung cancer (NSCLC): current status and future prospects.

A K Pathak1, M Bhutani, A Mohan, R Guleria, S Bal, V Kochupillai.   

Abstract

The incidence of lung cancer is rising dramatically and it is now the commonest cause of mortality and morbidity not only in the industrialised countries, but in developing nations like India as well. Tobacco smoking has consistently been demonstrated to be an important aetiological factor, though lung cancer occurs in non-smokers also. In spite of great advances in radiological and molecular diagnostic techniques, the ideal screening marker for early detection of lung cancer has still not been found. Histological diagnosis and staging is essential for selecting the mode of therapy in patients with lung cancer. Stages I and II are amenable to surgery. However, advanced stage III and IV need an individualised combination of surgery, chemotherapy and radiotherapy. With a better understanding of the cellular mechanisms operating in carcinogenesis, newer target specific modalities are being developed and tested in order to stem this disease, which threatens to assume epidemic proportions.

Entities:  

Mesh:

Year:  2004        PMID: 15553208

Source DB:  PubMed          Journal:  Indian J Chest Dis Allied Sci        ISSN: 0377-9343


  8 in total

1.  Detection of disease specific sialoglycoconjugate specific antibodies in bronchoalveolar lavage fluid of non-small cell lung cancer patients.

Authors:  Sangeeta Mehta; Rakhee Chhetra; Radhika Srinivasan; Suresh C Sharma; Digambar Behera; Sujata Ghosh
Journal:  Glycoconj J       Date:  2010-05-16       Impact factor: 2.916

2.  Elevated plasma interleukin-35 levels predict poor prognosis in patients with non-small cell lung cancer.

Authors:  Xiaobin Gu; Tian Tian; Bo Zhang; Yang Liu; Chao Yuan; Lijuan Shao; Yajun Guo; Kexing Fan
Journal:  Tumour Biol       Date:  2014-12-06

3.  Serum microRNA 125b as a diagnostic or prognostic biomarker for advanced NSCLC patients receiving cisplatin-based chemotherapy.

Authors:  En-hai Cui; Hong-jiao Li; Feng Hua; Bin Wang; Wei Mao; Xue-ren Feng; Jian-you Li; Xiang Wang
Journal:  Acta Pharmacol Sin       Date:  2012-09-17       Impact factor: 6.150

Review 4.  MicroRNAs as therapeutic targets in chemoresistance.

Authors:  Michela Garofalo; Carlo M Croce
Journal:  Drug Resist Updat       Date:  2013-06-10       Impact factor: 18.500

5.  Bevacizumab: the evidence for its clinical potential in the treatment of nonsmall cell lung cancer.

Authors:  Sonya Haslam; Paul Chrisp
Journal:  Core Evid       Date:  2007-03-31

Review 6.  Usage patterns of biomarkers in non-small-cell lung cancer patients in India: Findings from a systematic review and survey.

Authors:  Chirag Desai; Anurag Mehta; Divya Mishra
Journal:  Lung India       Date:  2014-07

7.  SNP rs16969968 as a Strong Predictor of Nicotine Dependence and Lung Cancer Risk in a North Indian Population

Authors:  Namita Pandey; Soumyadip Pal; Lokesh Kumar Sharma; Randeep Guleria; Anant Mohan; Tapasya Srivastava
Journal:  Asian Pac J Cancer Prev       Date:  2017-11-26

8.  RAGE genetic polymorphisms are associated with risk, chemotherapy response and prognosis in patients with advanced NSCLC.

Authors:  Xiang Wang; Enhai Cui; Huazong Zeng; Feng Hua; Bin Wang; Wei Mao; Xueren Feng
Journal:  PLoS One       Date:  2012-10-05       Impact factor: 3.240

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.